CBR96-doxorubicin immunoconjugate
Humanized (from mouse) | |
|---|---|
| Target | Lewis-Y antigen |
| Clinical data | |
| Other names | SGN-15, BMS-182248 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
cBR96-doxorubicin immunoconjugate (BMS-182248/SGN-15; also known as cBR96-Dox) is an
antibody-drug conjugate or (ADC) directed to the Lewis-Y antigen designed for the treatment of cancer. The payload is the chemotherapy drug doxorubicin which is connected with a hydrazone linker to cysteine residues of the Lewis-Y specific (chimeric) monoclonal antibody BR96.[1]
Following internalization, the hydrazone is hydrolyzed within the acidic environment of target cell endosomes and lysosomes to release active cytotoxic drug.
Clinical Development
In clinical trials cBR96-Dox was found to be highly active in regressing large human tumor xenografts implanted in mice or rats.[2][3] Multiple tumor models including lung, breast and colon were evaluated, and cBR96-Dox was found to have broad and potent anti-tumor activity, even in doxorubicin-resistant tumors.